STX18

Across TCGA pan-cancer cohorts, STX18 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STX18 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher STX18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STX18 expression acts as an unfavorable survival marker.

CESC, LUAD, and BLCA are the cancer types where STX18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.047	0.875	<.001	24	view →
LUAD	OS	Median	All	0.090	0.788	<.001	12	view →
BLCA	DFS	Median	All	0.139	0.626	.010	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

STX18–CESC (OS)

Open the CESC breakdown →